MAY 19, 2022
Comprehensive Ophthalmology, Oculoplastics/Orbit
0.5 General AMA PRA Category 1 Credits™
Drs. Seanna Grob and Alison Watson discuss approaches to ptosis (droopy eyelid), including evaluation, ancillary testing, and management. Drs. Grob and Watson review which patients may benefit from pharmacologic therapy such as oxymetazoline (Upneeq), and how they determine the best surgical approach in other cases.
For all episodes or to claim CME credit for selected episodes, visit www.aao.org/podcasts.
Release: May 19, 2022; expires May 19, 2025
Planner/Faculty: Dr. Sridhar reports no relevant financial disclosures.
Faculty: Drs. Seanna Grob and Alison Watson reports no relevant financial disclosures.
Review Panel: Dr. Mazeyar Saboori receives consulting and lecture fees from Aerie Pharmaceuticals. The following reviewers report no financial disclosures: Jeffrey D. Henderer, MD; Danah Albreiki, MBBS; Ashiyani Nariani, MD, MPH; Annie Moreau, MD; and Allison Umfress, MD.
Learning Objective: Upon completion of this episode, the listener should be able to describe evolving standards of care for ptosis, and outcomes from recent research and how these impact patient care decisions.
Audience: This activity is intended for comprehensive ophthalmologists.
Accreditation: The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Academy of Ophthalmology designates this internet enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hardware/Software Requirements: This learning activity requires a current web browser and speaker or headset capable of playing streaming audio.